M&A / Deals NewLimit’s $435M megaround; Lilly’s busy dealmaking week BioPharma DiveThe anti-aging biotech has secured one of the year s biggest venture fundings to bring its first drug into testing.Read full story pharminent June 3, 2026 (Last updated: June 4, 2026) BioPharma Dive The anti-aging biotech has secured one of the year s biggest venture fundings to bring its first drug into testing. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Travere beefs up rare kidney disease portfolio with up to $1.1B China dealNext: Legend surges on early data for ‘in vivo’ lymphoma cell therapy Related Stories M&A / Deals Supernus and Indivior merge to create CNS mega-company with 11 approved drugs pharminent August 3, 2026 M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026
